Answer

IFF Scent recovery: drivers, H2 trajectory for Fine Fragrance vs. Consumer Fragrance, and the R&D plan to support 2027

1) Drivers of Scent’s recovery (what changed and why it matters)

A. Strong momentum in Fragrance Ingredients is a key near-term tailwind to Scent performance

In Q2, Scent sales grew 8%, and management attributes a key driver to Fragrance Ingredients growing north of 20% in the quarter. ¹
The quarter’s strength is described as partly a favorable year-over-year comparison (Q2 comping against “a down 10% or more” prior-year period), but also partly due to commercial execution—the team leveraged the synthetics portfolio to capture more sales amid the macro environment, including supply chain disruptions and higher Brent crude prices. ¹
Management explicitly expects normalization: as conditions settle, Fragrance Ingredients growth should shift back toward higher value-added ingredients vs. traditional synthetics, and this is “understood” in the company’s second-half forecast. ¹

Analytical takeaway: Even though management notes normalization, the recovery narrative is supported by (i) strong recent wins and volume and (ii) a planned mix shift toward higher-value ingredients—both of which can support improved competitive positioning as you move toward 2027. ¹

B. Fine Fragrance: active management of regional volatility (Middle East) and recovery timing into Q4

For Fine Fragrance, the company notes that the Middle East conflict created volatility/noise but the Scent team managed the challenges effectively. ¹
Coming into Q2, Fine Fragrance growth was expected to be down mid-single digits, yet it finished slightly positive—evidence that demand/resourcing/actions held up better than feared. ¹
For the remainder of the year, management is factoring in a softer Q3 due to the shape of comparables and then expects recovery into Q4. ¹

Analytical takeaway: The recovery is not framed as “demand magically returning immediately,” but as disciplined navigation of uncertainty plus an expected improvement in the comparison profile—especially from Q3 to Q4. ¹

C. R&D capability and pipeline improvement is treated as a core structural driver

Leadership highlights a major improvement in the R&D pipeline over the last ~2.5 years: management says the pipeline “2.5 years ago was not what it should have been” but now they have a “very strong R&D capability,” including leading-edge perfumers, a pipeline of molecules and delivery systems, and a stronger R&D team. ²
Management also connects this to the current Scent strategy: “invest in R&D” and “grow your market share back,” with R&D being part of the mechanism to regain position. ³

Analytical takeaway: Management is positioning recovery as partly cyclical (comparables/normalization) and partly structural (R&D capability rebuilding and pipeline generation). ³²

2) How Fine Fragrance and Consumer Fragrance will evolve in the second half (growth-rate trajectory)

Fine Fragrance (H2 path)

Management expects Fine Fragrance to be “a little bit softer in Q3” and then “a stronger Q4,” leading to a second-half growth rate in the mid-single-digit range on that basis. ⁴

Consumer Fragrance (H2 path)

Consumer Fragrance is expected to be in the low single-digit growth range for the go-forward period. ⁴
Although Q2 was high single-digit, management expects it to normalize “on a go-forward basis to kind of a low single-digit number.” ⁴

Important context: R&D rebuild + market share gains are explicitly linked to Consumer Fragrance execution

Management says the team has done a good job on the compounds and has rebuilt the R&D capability, including the go-to-market approach with customers, aiming to drive market share gains in Consumer Fragrance. ⁴

Analytical takeaway: The company’s H2 “shape” is clearly guided by (i) Q3/Q4 timing for Fine Fragrance (softer then better) and (ii) normalization from a strong Q2 base for Consumer Fragrance—while R&D + go-to-market execution are positioned as the means to support market share recovery. ⁴

3) Plan for R&D to support 2027 (what management says they are building)

A. The company frames 2027 support as an extension of the rebuilt R&D engine completed over ~2.5 years

Management describes tangible improvements: stronger R&D capability, an improved pipeline of molecules and delivery systems, and leading-edge new Fine and Consumer Fragrances being developed by perfumers and the R&D team. ²
The recovery question is directly tied to “how you believe your R&D initiatives are going,” and management’s response indicates they are already using R&D as part of the recovery and market-share plan. ³²

B. R&D-linked competitive positioning is described as taking “time” for Fragrance Ingredients, with payoff into next year and “the year after”

Even though your question asks specifically about R&D to support 2027, the excerpts connect R&D efforts with longer lead-time product/mix changes:

Management states the shift to higher-value natural products in Fragrance Ingredients is underway but will take a little bit more time, and while it is “not in the second half of this year,” management expects a “really strong competitive position” as they progress into next year and the year after. ⁴

Analytical takeaway: The R&D and development efforts appear to be sequenced with product maturation windows: immediate H2 focuses on recovery dynamics and normalization, while the “next year and the year after” window (which aligns conceptually with supporting 2027 outcomes) is where management expects stronger competitive positioning from higher-value innovation/mix. ⁴

C. Reinforced reinvestment logic: R&D is part of the “innovation circle” tied to growth and margin

Management emphasizes that innovation/reinvestment matters because it creates a cycle where investments enable better growth, which supports margin expansion while still funding reinvestment. ⁵
R&D intensity is referenced as part of the ongoing strategy: the company notes being in an 8% to 9% range of sales for R&D and stresses the importance of continuing reinvestment to “set ourselves apart.” ⁵

Analytical takeaway: The plan for 2027 support is not described as one-off projects; it’s described as sustained R&D reinvestment with a measurable target intensity (8–9% of sales) plus a pipeline-development strategy that matures over time toward stronger competitive position. ⁵

Bottom line (directly answering the question)

Drivers of Scent recovery: Q2 strength (Scent sales +8%) led by Fragrance Ingredients growth north of 20%, supported by both year-over-year comp effects and strategic use of the synthetics portfolio amid macro/supply-chain conditions; Fine Fragrance also shows resilience via active management of Middle East volatility; and structurally, the company points to a rebuilt R&D capability/pipeline over ~2.5 years. ¹²³
Second-half evolution:
- Fine Fragrance: softer Q3, stronger Q4, yielding mid-single-digit growth in the second half. ⁴
- Consumer Fragrance: normalize from a high-single-digit Q2 toward low-single-digit go-forward growth. ⁴
R&D plan to support 2027: management emphasizes sustained reinvestment in innovation (8–9% of sales for R&D) and a stronger molecule + delivery system pipeline enabling leading-edge Fine/Consumer launches; additionally, development of higher-value product shifts (notably in Fragrance Ingredients) is described as taking longer, with expected stronger competitive positioning into next year and the year after, conceptually supporting the 2027 horizon. ⁵²⁴

References

International Flavors & Fragrances Inc. (IFF) earnings transcript 2026 - Q2

Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.

IFF Scent Recovery Gains Momentum in Q2 2026, H2 Outlook and 2027 R&D Plan

Sources used

Research question

Answer

IFF Scent recovery: drivers, H2 trajectory for Fine Fragrance vs. Consumer Fragrance, and the R&D plan to support 2027

1) Drivers of Scent’s recovery (what changed and why it matters)

A. Strong momentum in Fragrance Ingredients is a key near-term tailwind to Scent performance

B. Fine Fragrance: active management of regional volatility (Middle East) and recovery timing into Q4

C. R&D capability and pipeline improvement is treated as a core structural driver

2) How Fine Fragrance and Consumer Fragrance will evolve in the second half (growth-rate trajectory)

Fine Fragrance (H2 path)

Consumer Fragrance (H2 path)

Important context: R&D rebuild + market share gains are explicitly linked to Consumer Fragrance execution

3) Plan for R&D to support 2027 (what management says they are building)

A. The company frames 2027 support as an extension of the rebuilt R&D engine completed over ~2.5 years

B. R&D-linked competitive positioning is described as taking “time” for Fragrance Ingredients, with payoff into next year and “the year after”

C. Reinforced reinvestment logic: R&D is part of the “innovation circle” tied to growth and margin

Bottom line (directly answering the question)

References

Keep Reading

IFF's Scent Recovery Gains Traction as Fine and Consumer Fragrance Evolve in 2H 2026

Keep Reading

Keep Reading

IFF's Scent Recovery Gains Traction as Fine and Consumer Fragrance Evolve in 2H 2026

IFF Scent Recovery Gains Momentum in Q2 2026 with Second-Half Outlook

IFF's Scent Recovery Fueled by 2026 Q2 R&D Reboot; H2 Outlook and 2027 Plan

IFF’s Scent Recovery Driven by Fragrance Ingredients, R&D Push Toward 2027 in Q2 2026

IFF Scent Recovery Driven by Fragrance Ingredients, 2H 2026 Outlook, and 2027 R&D Plan

IFF Scent Recovery Fueled by Fragrance Ingredients, Q2 2026 Outlook, and 2027 R&D Plan

IFF Scent Recovery Strengthens as Q2 2026 Highlights R&D Path to 2027

IFF Scent Recovery Gains Traction in Q2 2026, R&D Plan Sets 2027 Outlook

IFF Scent Recovery Gains Momentum in 2H, R&D Plan Targets 2027

IFF Scent Recovery Driven by Fragrance Ingredients; H2 Outlook and 2027 R&D Plan

IFF's Scent Recovery Fueled by Fragrance Ingredients Momentum and 2027 R&D Plan

IFF Q2 2026 Highlights on Scent Recovery, H2 Fragrance Outlook, and 2027 R&D Plan